Providence Capital Advisors’s Boston Scientific BSX Stock Holding History

Providence Capital Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.21M	Sell	67,100 -500	-0.7%	-$40K	0.69%	61
2025 Q4	$6.45M	Buy	+67,600	New	+$6.63M	1.08%	37
2022 Q1	–	Sell	-96,410	Closed	-$4.09M	–	468
2021 Q4	$4.09M	Buy	96,410 +13,810	+17%	+$580K	1.13%	37
2021 Q3	$3.58M	Buy	+82,600	New	+$3.65M	1.12%	41
2018 Q1	–	Sell	-70,000	Closed	-$1.74M	–	251
2017 Q4	$1.74M	Buy	+70,000	New	+$1.93M	1.34%	28

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Providence Capital Advisors's BSX Position: Q1 2026 in Review

Providence Capital Advisors reduced its Boston Scientific (BSX) stake by 0.74% in Q1 2026, selling an estimated $40K and leaving 67,100 shares worth $4.21M. The position accounts for 0.69% of the portfolio, ranked #61.

Providence Capital Advisors first reported a position in BSX in Q4 2017 and has held it in 5 quarters since. The position peaked at $6.45M in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Providence Capital Advisors held 67,100 shares of Boston Scientific worth $4.21M as of Q1 2026.
Providence Capital Advisors sold 500 Boston Scientific shares in Q1 2026, an estimated $40K.
Boston Scientific made up 0.69% of Providence Capital Advisors's portfolio in Q1 2026, its #61 holding.
Providence Capital Advisors first reported a position in Boston Scientific in Q4 2017 and has held it in 5 quarters since.
Providence Capital Advisors's Boston Scientific position peaked at $6.45M in Q4 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Providence Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.